Woodline Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Woodline Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.8M	Buy	845,800 +392	+0%	+$5.51K	0.04%	472
2025 Q4	$10.2M	Buy	845,408 +118	+0%	+$1.6K	0.04%	459
2025 Q3	$11.5M	Sell	845,290 -355,000	-30%	-$3.34M	0.05%	407
2025 Q2	$7.69M	Sell	1,200,290 -409,157	-25%	-$1.99M	0.04%	479
2025 Q1	$5.7M	Buy	+1,609,447	New	+$5.73M	0.04%	474
2024 Q3	–	Sell	-523,772	Closed	-$995K	–	599
2024 Q2	$995K	Hold	523,772	–	–	0.01%	463
2024 Q1	$1.49M	Buy	523,772 +52,971	+11%	+$693K	0.01%	444
2023 Q4	$6.93M	Sell	470,801 -428,499	-48%	-$6.57M	0.08%	272
2023 Q3	$16.5M	Hold	899,300	–	–	0.19%	156
2023 Q2	$19.4M	Buy	899,300 +465,100	+107%	+$12.6M	0.23%	132
2023 Q1	$12.7M	Sell	434,200 -74,153	-15%	-$2.58M	0.17%	170
2022 Q4	$18.8M	Sell	508,353 -512,031	-50%	-$18.2M	0.25%	118
2022 Q3	$28.7M	Buy	1,020,384 +630,155	+161%	+$15.7M	0.4%	66
2022 Q2	$7.52M	Hold	390,229	–	–	0.12%	207
2022 Q1	$5.01M	Buy	+390,229	New	+$8.81M	0.08%	244

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Woodline Partners's AMLX Position: Q1 2026 in Review

Woodline Partners increased its Amylyx Pharmaceuticals (AMLX) stake by 0.05% in Q1 2026, buying an estimated $5.51K and bringing the position to 845,800 shares worth $11.8M. The position accounts for 0.04% of the portfolio, ranked #472.

Woodline Partners first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $28.7M in Q3 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Woodline Partners held 845,800 shares of Amylyx Pharmaceuticals worth $11.8M as of Q1 2026.
Woodline Partners bought 392 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $5.51K.
Amylyx Pharmaceuticals made up 0.04% of Woodline Partners's portfolio in Q1 2026, its #472 holding.
Woodline Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
Woodline Partners's Amylyx Pharmaceuticals position peaked at $28.7M in Q3 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.